TY - JOUR T1 - A SMAD4-modulated gene profile predicts disease-free survival in stage II and III colorectal cancer JF - medRxiv DO - 10.1101/2020.02.16.20023663 SP - 2020.02.16.20023663 AU - Bryan C. Szeglin AU - Chao Wu AU - Michael R. Marco AU - Hyun Sung Park AU - Zeda Zhang AU - Bing Zhang AU - Julio Garcia-Aguilar AU - R. Daniel Beauchamp AU - Xi Chen AU - J. Joshua Smith Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/02/20/2020.02.16.20023663.abstract N2 - Objective Loss of SMAD4 is associated with worse outcomes for colorectal cancer patients. We used gene ontology and bioinformatics to identify an RNA-based SMAD4-modulated profile and test its association with patient outcome.Design Using a discovery dataset of 250 colorectal cancer patients, we analyzed expression of BMP/Wnt target genes for association with SMAD4 expression. Promoters of the BMP/Wnt genes were interrogated for SMAD-binding elements. 15 genes were implicated and three tested for modulation by SMAD4 in patient-derived colorectal cancer tumoroids. Expression of the 15 genes was used for unsupervised hierarchical clustering of a training dataset and two resulting clusters modeled in a centroid model. This model was applied to an independent validation dataset of stage II and III patients. Disease-free survival was analyzed by the Kaplan-Meier method.Results In vitro analysis of three genes identified in the SMAD4-modulated profile (JAG1, TCF7, MYC) revealed modulation by SMAD4 consistent with the trend observed in the profile. In the training dataset (n = 553), the profile was not associated with outcome. However, among stage II and III patients (n = 461), distinct clusters were identified by unsupervised hierarchical clustering that were associated with disease-free survival (p = 0.02). The main model was applied to a validation dataset (n = 257) which confirmed the association of clustering with disease-free survival (p = 0.02).Conclusions A SMAD4-modulated RNA-based gene profile identified high-risk stage II and III colorectal cancer patients, can predict disease-free survival, and has prognostic potential for stage II and III colorectal cancer patients.Competing Interest StatementJ.J.S. has received travel support for fellow education from Intuitive Surgical Inc. J.J.S. also served as clinical advisor for Guardant Health, Inc. J.G.A. has received support from Medtronic (honorarium for consultancy with Medtronic), Johnson & Johnson (honorarium for delivering a talk), and Intuitive Surgical (honorarium for participating in a webinar by Intuitive Surgical). All other authors declare that they have no competing interests. Funding StatementThis research was supported by the National Institutes of Health (P30 CA008748, P30 CA068485, P50 CA095103, R01 CA069457, and R01 CA158472). J.J.S. was supported by NIH/NCI grant 5R01-CA182551-04 and the MSK Colorectal Cancer Research Center. J.J.S. is also supported by the American Society of Colon and Rectal Surgeons Career Development Award, the Joel J. Roslyn Faculty Research Award, the American Society of Colon and Rectal Surgeons Limited Project Grant, the MSK Department of Surgery Junior Faculty Award, and the John Wasserman Colon and Rectal Cancer Fund. J.J.S. is also supported by the Colorectal Cancer Alliance and the Chris4Life Research Award. The work was funded in part by a Stand Up to Cancer (SU2C) Colorectal Cancer Dream Team Translational Research Grant (Grant Number: SU2C: AACR-DR22-17). Stand Up to Cancer is a program of the Entertainment Industry Foundation. Research grants are administered by the American Association of Cancer Research, the scientific partner of SU2C. J.J.S. is partly supported by a loan repayment grant from the NIH via the National Cancer Institute for this work. J.J.S. is also supported in part by funding from the Howard Hughes Medical Institute via C.L.S. BCS is supported by the Einstein Research Fellowship through the Albert Einstein College of Medicine.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe discovery dataset (VUMC and MCC) will be deposited in the Gene Expression Omnibus (GEO) repository upon publication. Prior to publication, these data are available on request. The other datasets used in this study are also available publicly through the GEO repository as follows: Training: Dataset, GSE39582 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE39582); Validation: GSE33113 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE33113), GSE31595 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31595), GSE37892 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE37892). https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE39582 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE33113 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31595 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE37892 CRCcolorectal cancerTGF-βtransforming growth factor-betaBMPbone morphogenetic proteinIHCimmunohistochemistryVUMCVanderbilt University Medical CenterMCCMoffitt Cancer CenterSBESMAD-binding elementsgRNAsingle-guide RNADFSdisease-free survival ER -